Precision BioSciences Overview and Financial Performance

Precision BioSciences is a biotechnology company that has been making waves in the industry with its innovative approach to gene editing. Founded in 2004, the company has been working on developing a proprietary gene editing platform called ARCUS.

Precision BioSciences has a strong financial foundation, with a market capitalization of over $1 billion. This significant investment has allowed the company to continue its research and development efforts.

The company's financial performance has been impressive, with a revenue growth rate of 100% in 2020. This rapid growth is a testament to the company's innovative approach and its ability to execute on its business plan.

Precision BioSciences has also received significant funding from investors, including a $175 million series E funding round in 2020.

Broaden your view: Wiki-PR Wikipedia Editing Scandal

Precision BioSciences was founded in March 2006 by Derek Jantz, Jeff Smith, and Matt Kane, a student at the Duke Fuqua School of Business at the time.

The company started out with early funding rounds, first a Series A round led by venBio to develop its genome editing platform, and then a Series B round to fund product development efforts.

Precision BioSciences completed its initial public offering in 2019, trading under the Nasdaq ticker DTIL.

In November 2020, the company entered into a partnership with Eli Lilly to use its ARCUS editing technology for up to six in vivo targets connected to genetic disorders.

The partnership began with Duchenne muscular dystrophy, a severe genetic disorder that affects muscle strength and function.

Michael Amoroso, former CEO of Abeona Therapeutics, took over as President and CEO of Precision BioSciences in October 2021, succeeding Matt Kane.

That same year, Precision announced two more collaborations, one with Tiziana Life Sciences to explore using foralumab for CAR T cell therapy, and another with iECURE to advance candidates into clinical trials and investigate liver disease treatment.

A different take: Quality Control and Genetic Algorithms

Precision BioSciences has an annual revenue of $75.1 million in 2025. This is a significant milestone for the company, indicating its steady growth and progress in the industry.

The company's financial performance is a testament to its innovative approach and commitment to delivering high-quality products and services.

Precision BioSciences, Inc. reported an annual revenue of $75.1 million in 2025.

The company's financial performance is a crucial aspect of its overall success.

In 2025, Precision BioSciences, Inc. achieved a significant milestone with its annual revenue.

This revenue figure is a testament to the company's growth and expansion in the industry.

If you're looking to identify a company's NAICS code, Precision BioSciences, Inc. has a code of 54.

For companies in the scientific and technical services industry, the NAICS code 541 is often relevant.

The NAICS code for Precision BioSciences, Inc. also includes 32541, which is a specific code for research and development in the physical, engineering, and life sciences sector.

In some cases, companies may also have a NAICS code of 3254, which is related to the manufacturing of chemicals and allied products.

Precision BioSciences, Inc. has a NAICS code of 325, which is a broader category for the manufacture of chemicals.

Take a look at this: Bank Naics Code

Analysts' Consensus is a crucial aspect of understanding the stock market. It's a snapshot of what experts think about a particular company's performance.

The analysts' consensus for Precision BioSciences' Q2 earnings is a key indicator of their expectations. They're looking at the company's stock market performance to make informed decisions.

Here are some specific areas where analysts have a consensus:

These areas are closely related to the company's Q2 earnings snapshot, which provides a detailed look at their financial performance.

Precision BioSciences' leadership team is comprised of experienced professionals with a strong track record in biotechnology and gene editing.

The company's CEO, Matt Kane, has a deep understanding of the gene editing market and has been instrumental in shaping the company's strategy.

Precision BioSciences' management team has a strong focus on innovation, with a significant portion of their budget allocated to research and development.

This commitment to innovation has led to the development of the company's proprietary ARCUS technology, which enables precise and efficient gene editing.

On a similar theme: Strong Dollar Policy

Under the leadership of Matt Kane, Precision BioSciences has been able to attract top talent in the industry, including experts in gene editing and biotechnology.

The company's management team is dedicated to translating their technology into real-world applications, with a focus on treating serious diseases such as cancer and genetic disorders.

At Precision BioSciences, research and development are cornerstones of the company's mission. They have developed a proprietary gene editing platform called Arcelera, which enables the precise and efficient editing of genes.

Their Arcelera platform is based on a type of CRISPR-Cas9 gene editing, but with some key differences that make it more precise and efficient. Precision BioSciences has also developed a proprietary technology called ARC, which stands for Arcelera RNA-Cas9.

Their research and development efforts have led to the creation of a number of innovative products, including a treatment for certain types of cancer.

Related reading: Resampled Efficient Frontier

Precision BioSciences' proprietary technology is the ARCUS platform and ARCUS nucleases, which are based on a naturally occurring genome editing enzyme, I-CreI.

ARCUS nucleases can make highly specific cuts and DNA insertions in cellular DNA, and are much smaller in size than CRISPR spCas9. They can use either adeno-associated virus (AAV) vectors or lipid nanoparticles (LNPs) for delivery to specific tissues and cells.

The ARCUS nuclease can deactivate itself once gene edits are made, which minimizes potential off-targeting. This is a key advantage of the ARCUS platform.

Precision has used ARCUS nucleases to develop multiple ex vivo allogeneic, "off-the-shelf" CAR T cell immunotherapies in early-stage clinical trials. These treatments show promise for treating various diseases.

ARCUS nucleases generate a unique cleavage site in DNA that is characterized by four-base-pair, 3' overhangs. This allows for efficient multiplexing of edits.

The ARCUS platform has been used to treat ornithine transcarbamylase deficiency in newborn nonhuman primates and chronic Hepatitis B using a LNP.

Precision is developing multiple candidates targeting non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma.

Discover more: Enterprise Value Multiples

Their lead candidate, PBCAR0191, received orphan drug designation for the treatment of ALL and mantle cell lymphoma, and fast track designation for B-cell ALL.

PBCAR0191 began its Phase 1/2a clinical trial in March 2019.

In June 2022, Precision reported a 100% response rate, 73% complete response rate, and 50% durable response rate.

Precision is also developing PBCAR19B, an anti-CD19 stealth cell candidate that employs a single gene edit to knock down beta-2 microglobulin.

A Phase 1 study for PBCAR19B began in June 2021.

PBCAR269A, an investigational allogeneic B-cell maturation antigen-targeted CAR T cell therapy, is being evaluated for the treatment of multiple myeloma.

PBCAR269A began its Phase 1 trials in April 2020 and moved onto recruitment for its Phase 1/2a study in July 2022.

The FDA granted fast track designation to PBCAR269A for the treatment of relapsed or refractory multiple myeloma in 2020.

You might like: Multiple Factor Models

Precision BioSciences has been making waves in the scientific community with its innovative gene editing technology. The company announced a late-breaking oral presentation for PBGENE-HBV at AASLD The Liver Meeting 2025 on October 14.

Precision BioSciences has also been actively publishing its research findings. A recent publication in Nucleic Acids Research elucidated the mechanisms for high efficiency gene insertion in dividing and non-dividing cells using ARCUS Nucleases.

The company has been expanding its clinical trial sites, with the first U.S. site opening for the Eliminate-B trial on October 7. Precision BioSciences also presented phase 1 PBGENE-HBV trial data at the HBV Cure Symposium on September 12.

In a significant development, Precision BioSciences received FDA orphan drug designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy on July 23. The company also received FDA rare pediatric disease designation for PBGENE-DMD on June 25.

Here are some key dates for Precision BioSciences' recent developments: